
Sientra SIEN
Quarterly report 2023-Q3
added 11-13-2023
Sientra Book Value 2011-2026 | SIEN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Sientra
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 40.9 M | -557 K | 81.9 M | 66.9 M | 27.6 M | 83.6 M | 119 M | 95.6 M | -127 M | -108 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | -127 M | 28 M |
Quarterly Book Value Sientra
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32 M | -18.6 M | - | -409 K | -4.33 M | 8.67 M | 25.1 M | 40.9 M | 40.8 M | -30.9 M | -12.9 M | -557 K | -557 K | -557 K | -557 K | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 66.9 M | 66.9 M | 66.9 M | 66.9 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 119 M | 119 M | 119 M | 119 M | 95.6 M | 95.6 M | 95.6 M | 95.6 M | 23.8 M | 23.8 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | -32 M | 49 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abbott Laboratories
ABT
|
86.7 B | $ 102.87 | 0.48 % | $ 179 B | ||
|
Align Technology
ALGN
|
3.85 B | $ 170.6 | -1.23 % | $ 12.8 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 10.83 | -3.82 % | $ 1.63 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
129 M | $ 34.44 | 2.56 % | $ 1.59 B | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 9.37 | 2.52 % | $ 265 M | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 0.42 | 6.82 % | $ 43.2 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.58 | 6.52 % | $ 36.1 M | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.63 | 0.94 % | $ 345 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Electromed
ELMD
|
43.2 M | $ 23.29 | -1.52 % | $ 197 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 36.76 | 1.88 % | $ 5.48 K | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 62.82 | 1.32 % | $ 93 B | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 81.05 | -0.26 % | $ 47.4 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 34.79 | -2.08 % | $ 1.08 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Aethlon Medical
AEMD
|
5.12 M | $ 2.12 | -1.4 % | $ 3.31 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.03 | 1.43 % | $ 1.63 B | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.86 | 9.41 % | $ 1.13 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 9.53 | -0.42 % | $ 734 M | ||
|
Inogen
INGN
|
192 M | $ 6.21 | -0.96 % | $ 165 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 54.99 | 2.52 % | $ 1.61 B | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 16.06 | -1.41 % | $ 377 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 0.98 | 3.17 % | $ 16.6 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 86.85 | 0.47 % | $ 3.02 B | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 63.79 | -1.3 % | $ 3.48 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 6.06 | 1.51 % | $ 72.5 M |